$HALB Halberd Engages Professional Firm to Proceed
Post# of 36313
(Total Views: 161)
Posted On: 05/18/2022 1:07:07 PM
$HALB Halberd Engages Professional Firm to Proceed with FDA Filings
https://www.accesswire.com/701668/halberd-eng...da-filings
JACKSON CENTER, PA / ACCESSWIRE / May 18, 2022 / Halberd Corporation (OTC PINK:HALB) has engaged the services of mdi Consultants, Inc. (mdi) to assist Halberd in navigating the U.S. Food and Drug Administration's (FDA) complex application and certification processes. mdi will guide Halberd on the FDA application and testing protocol and assist in filing the appropriate documents and disclosures with the FDA in each stage of the process. After numerous discussions, Halberd is confident that mdi is the right choice to effectively and efficiently facilitate this significant milestone in Halberd's monumental and groundbreaking, historic journey.
Alan Schwartz, Executive Vice-President of mdi Consultants, Inc., commented, "We look forward to assisting Halberd's new technology through the FDA review process. mdi has 44 years of regulatory experience and has successfully guided over 4,000 devices/products through the FDA review process."
William A. Hartman, Chairman, President & CEO of Halberd Corporation, stated, "Halberd recognizes that it does not have the expertise required to efficiently and effectively navigate the intracacies of the FDA's application process for new drugs and devices. The expertise that mdi brings to the table will fill that gap and speed us along in our quest to get FDA certification for our groundbreaking patented and patent-pending devices, antibodies and associated drugs."
To get the latest news on Halberd's exciting developments, subscribe by submitting this form.
(https://halberdcorporation.com/contact-us/)
https://www.accesswire.com/701668/halberd-eng...da-filings
JACKSON CENTER, PA / ACCESSWIRE / May 18, 2022 / Halberd Corporation (OTC PINK:HALB) has engaged the services of mdi Consultants, Inc. (mdi) to assist Halberd in navigating the U.S. Food and Drug Administration's (FDA) complex application and certification processes. mdi will guide Halberd on the FDA application and testing protocol and assist in filing the appropriate documents and disclosures with the FDA in each stage of the process. After numerous discussions, Halberd is confident that mdi is the right choice to effectively and efficiently facilitate this significant milestone in Halberd's monumental and groundbreaking, historic journey.
Alan Schwartz, Executive Vice-President of mdi Consultants, Inc., commented, "We look forward to assisting Halberd's new technology through the FDA review process. mdi has 44 years of regulatory experience and has successfully guided over 4,000 devices/products through the FDA review process."
William A. Hartman, Chairman, President & CEO of Halberd Corporation, stated, "Halberd recognizes that it does not have the expertise required to efficiently and effectively navigate the intracacies of the FDA's application process for new drugs and devices. The expertise that mdi brings to the table will fill that gap and speed us along in our quest to get FDA certification for our groundbreaking patented and patent-pending devices, antibodies and associated drugs."
To get the latest news on Halberd's exciting developments, subscribe by submitting this form.
(https://halberdcorporation.com/contact-us/)
(0)
(0)